Diabetic endothelial microangiopathy and pulmonary dysfunction.
Front Endocrinol (Lausanne)
; 14: 1073878, 2023.
Article
in English
| MEDLINE | ID: covidwho-2306422
ABSTRACT
Type 2 diabetes mellitus (T2DM) is a widespread metabolic condition with a high global morbidity and mortality rate that affects the whole body. Their primary consequences are mostly caused by the macrovascular and microvascular bed degradation brought on by metabolic, hemodynamic, and inflammatory variables. However, research in recent years has expanded the target organ in T2DM to include the lung. Inflammatory lung diseases also impose a severe financial burden on global healthcare. T2DM has long been recognized as a significant comorbidity that influences the course of various respiratory disorders and their disease progress. The pathogenesis of the glycemic metabolic problem and endothelial microangiopathy of the respiratory disorders have garnered more attention lately, indicating that the two ailments have a shared history. This review aims to outline the connection between T2DM related endothelial cell dysfunction and concomitant respiratory diseases, including Coronavirus disease 2019 (COVID-19), asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Vascular Diseases
/
Pulmonary Disease, Chronic Obstructive
/
Diabetes Mellitus, Type 2
/
Diabetic Angiopathies
/
Idiopathic Pulmonary Fibrosis
/
COVID-19
Type of study:
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Front Endocrinol (Lausanne)
Year:
2023
Document Type:
Article
Affiliation country:
Fendo.2023.1073878
Similar
MEDLINE
...
LILACS
LIS